
    
      This research study will be a prospective, open-label 18-week clinical study of nebivolol in
      patients with PH associated with HFpEF. Patients will be identified in clinic based on
      echocardiogram (TTE) and right heart catheterization (RHC) results (both part of standard
      clinical care) indicating PH and HFpEF.
    
  